Dizal (Jiangsu) Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2017-10-27
- Employees
- 581
- Market Cap
- -
- Website
- http://www.dizalpharma.com
Clinical Trials
10
Active:3
Completed:2
Trial Phases
2 Phases
Phase 1:4
Not Applicable:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Not Applicable
4 (44.4%)Phase 1
4 (44.4%)phase_1_2
1 (11.1%)A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
Not Applicable
Not yet recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT07182682
- Locations
- 🇨🇳
Beijing Chest Hospital, Capital medical university, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳China-Japan Friendship hospital, Beijing, China
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Not Applicable
Not yet recruiting
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT07154264
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Not Applicable
Not yet recruiting
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT07139873
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Not Applicable
Not yet recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT07079475
DZD9008 PK Study in Hepatic Impairment Subjects
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT06084104
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸American Research Corporation, San Antonio, Texas, United States
- Prev
- 1
- 2
- Next
News
No news found